- Home
- PBYI vs NRO Comparison
PBYI vs NRO Comparison
Compare PBYI & NRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- NRO
- Stock Information
- Founded
- PBYI 2010
- NRO 2003
- Country
- PBYI United States
- NRO United States
- Employees
- PBYI N/A
- NRO N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- NRO Finance/Investors Services
- Sector
- PBYI Health Care
- NRO Finance
- Exchange
- PBYI Nasdaq
- NRO Nasdaq
- Market Cap
- PBYI 164.3M
- NRO 156.7M
- IPO Year
- PBYI N/A
- NRO N/A
- Fundamental
- Price
- PBYI $3.45
- NRO $3.24
- Analyst Decision
- PBYI Strong Buy
- NRO
- Analyst Count
- PBYI 1
- NRO 0
- Target Price
- PBYI $7.00
- NRO N/A
- AVG Volume (30 Days)
- PBYI 307.3K
- NRO 239.4K
- Earning Date
- PBYI 07-31-2025
- NRO 01-01-0001
- Dividend Yield
- PBYI N/A
- NRO 11.41%
- EPS Growth
- PBYI 143.51
- NRO N/A
- EPS
- PBYI 0.77
- NRO N/A
- Revenue
- PBYI $232,709,000.00
- NRO N/A
- Revenue This Year
- PBYI N/A
- NRO N/A
- Revenue Next Year
- PBYI N/A
- NRO N/A
- P/E Ratio
- PBYI $4.43
- NRO N/A
- Revenue Growth
- PBYI 2.68
- NRO N/A
- 52 Week Low
- PBYI $2.23
- NRO $2.51
- 52 Week High
- PBYI $4.13
- NRO $3.45
- Technical
- Relative Strength Index (RSI)
- PBYI 50.12
- NRO 52.08
- Support Level
- PBYI $3.26
- NRO $3.19
- Resistance Level
- PBYI $3.68
- NRO $3.27
- Average True Range (ATR)
- PBYI 0.12
- NRO 0.04
- MACD
- PBYI 0.00
- NRO 0.00
- Stochastic Oscillator
- PBYI 52.90
- NRO 65.00
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").